BRAF and non-small cell lung carcinoma: As shown in Table 2, NF1 mutant patients exhibited concurrent TP53, BRAF, or RASA1 mutations; NF1 mutations were mutually exclusive with EGFR mutations in 118 NF1 mutant NSCLC patients and 236 NF1 wild‐type NSCLC patients.